Ignite Creation Date:
2025-12-24 @ 11:33 PM
Ignite Modification Date:
2025-12-25 @ 9:21 PM
Study NCT ID:
NCT04300556
Status:
RECRUITING
Last Update Posted:
2025-11-14
First Post:
2020-03-06
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRĪ±)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Sponsor:
Eisai Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-08-06
Start Date Type:
ACTUAL
Primary Completion Date:
2030-08-08
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-08-08
Completion Date Type:
ESTIMATED
First Submit Date:
2020-03-06
First Submit QC Date:
None
Study First Post Date:
2020-03-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-12
Last Update Post Date:
2025-11-14
Last Update Post Date Type:
ESTIMATED